Involvement of RB kinases and phosphatases in life and death decisions

Oncology Reports

Volumn 4, Issue 6, 1997, Pages 1129-1134

  An, Bing ^a   Dineley, Kirk E ^a   Zhang, Lei Lei ^a   Termin, Toni A ^a   Meijer, Laurent ^b   Dou, Q Ping ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b STATION BIOLOGIQUE   (France)

Author keywords

Apoptosis; cdk inhibitors; cdks; Phosphatases; Protein kinases C; RB

Indexed keywords

CALYCULIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA FRAGMENT; INHIBITOR PROTEIN; OKADAIC ACID; PHOSPHATASE; PROTEIN KINASE C INHIBITOR; RETINOBLASTOMA PROTEIN; ROSCOVITINE; SPHINGOSINE; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEATH; DEPHOSPHORYLATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIFE; PRIORITY JOURNAL;

EID: 0030883187     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.6.1129     Document Type: Article

References (38)

1. Wang JY, Knudsen ES and Welch PJ: The retinoblastoma tumor suppressor protein. Adv Cancer Res 64: 25-85, 1994.
2. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
3. Hunter T and Pines J: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
4. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
5. Ludlow JW, Glendening CL, Livingston DM and De Carprio JA: Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 13: 367-372, 1993.
6. Morgan DO: Principles of CDK regulation. Nature 374: 131-135, 1995.
7. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
8. Parry D, Bates S, Mann DJ and Peters G: Lack of cyclin D-Cdk complexes in RB-negative cells correlates with high levels of p16/INK4/MTS1 tumor suppressor gene product. EMBO J 14: 503-511, 1995.
9. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
10. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 806-816, 1993.
11. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L and Swindell E: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387-400, 1995.
12. Poon RYC, Jiang W, Toyoshima H and Hunter T: Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271: 13283-13291, 1996.
13. Zhou W, Takuwa N, Kumada M and Takuwa Y: E2F1, B-Myb and selective members of cyclin/cdk subunits are targets for protein kinase C-mediated bimodal growth regulation in vascular endothelial cells. Biochem Biophys Res Commun 199: 191-198, 1994.
14. Tamaoki T: Use and specificity of staurosporine, UCN-01 and calphostin C as protein kinase inhibitors. Methods Enzymol 201: 340-347, 1991.
15. Gong J, Traganos F and Darzynkiewicz Z: Staurosporine blocks cell progression through G1 between the cyclin D and cyclin E restriction points. Cancer Res 54: 3136-3139, 1994.
16. Kwon TK, Buchholz MA, Chrest FJ and Nordin AA: Staurosporine-induced G1 arrest is associated with the induction and accumulation of cyclin-dependent kinase inhibitors. Cell Growth Differ 7: 1305-1313, 1996.
17. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y and Yasuda H: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432, 1993.
18. Losiewicz MD, Carlson BA, Kaur G, Sausville EA and Worland PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201: 589-595, 1994.
19. Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
20. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6: 393-397, 1996.
21. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536, 1997.
22. Dou QP: Putative roles of retinoblastoma protein in apoptosis. Apoptosis 2: 5-18, 1997.
23. Dou QP, An B and Will PW: Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci USA 92: 9019-9023, 1995.
24. Wang H, Grand RJA, Milner AE, Armitage RJ, Gordon J and Gregory CD: Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. Oncogene 13: 373-379, 1996.
25. Morana SJ, Wolf CM, Li J, Reynolds JE, Brown MK and Eastman A: The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. J Biol Chem 271: 18263-18271, 1996.
26. Hannun YA, Loomis CR, Merrill AH Jr and Bell RM: Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 261: 12604-12609, 1996.
27. Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR and Gewirtz DA: Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res 52: 6270-6278, 1992.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Mem 139: 271-279, 1991.
29. Dou QP, Levin AH, Zhao S and Pardee AB: Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res 53: 1493-1497, 1993.
30. Suganuma M, Fujiki H, Furuya-Suguri H, Yoshizawa S, Yasumoto S, Kato Y, Fusetani N and Sugimura T: Calyculin A, an inhibitor of protein tumor promoter on CD-1 mouse skin. Cancer Res 50: 3521-3525, 1990.
31. Cohen P, Holmes CFB and Tsukitani Y: Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci 15: 98-102, 1990.
32. Janicke RU, Walker PA, Lin XY and Porter AG: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969-6978, 1996.
33. Chen W, Otterson GA, Lipkowitz S, Khleif SN, Coxon AB and Kaye FJ: Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 14: 1243-1248, 1997.
34. Tan X, Martin SJ, Green DR and Wang JYJ: Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death. J Biol Chem 272: 9613-9616, 1997.
35. Durfee T, Becherer K, Chen PL, Yeh SH, Yang Y, Kilburn AE, Lee WH and Elledge SJ: The retinoblastoma protein associates ( with the protein phosphatase 1 catalytic subunit. Genes Dev 7: 555-569, 1993.
36. Ongkeko W, Ferguson DJP, Harris AL and Norbury C: Inactivation of cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci 108: 2897-2904, 1995.
37. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S and Seyama T: Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56: 3862-3865, 1996.
38. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.